Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidate include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis. The company also develops PF743, a recombinant crisantaspase; PF745, a recombinant crisantaspase with half-life extension technology; and PF810, a peptide based next generation therapeutic which is in preclinical development, as well as offers sparX-1 (PF753) and sparX-2 (PF754). In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California. As of September 29, 2020, Pfenex Inc. operates as a subsidiary of Ligand Pharmaceuticals Incorporated.
Research context
Pfenex Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Pfenex Inc is currently in a long term uptrend where the price is trading 30.8% above its 200 day moving average.
From a valuation standpoint, the stock is 99.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.4.
Based on the above factors, Pfenex Inc gets an overall score of 2/5.